Tailoring Treatment in Localized Prostate Cancer: Comparative Effectiveness of HIFU, Cryoablation, and Robot-Assisted Radical Prostatectomy at 2-Year Follow-Up: Insights from Prospective Institutional Cohort
<b>Background:</b> In the evolving landscape of localized prostate cancer management, focal therapies such as high-intensity focused ultrasound (HIFU) and prostate gland cryoablation (PGC) have emerged as organ-sparing alternatives for patients with low- to intermediate-risk disease. While these strategies aim to preserve functional outcomes, comparative data against robot-assisted radical prostatectomy (RARP) remain scarce and heterogeneous. <b>Methods:</b> We conducted a prospective, single-center study evaluating oncologic and functional outcomes in patients with organ-confined prostate cancer (Grade Group ≤ 2) treated with HIFU (<i>n</i> = 49), PGC (<i>n</i> = 114), or RARP (<i>n</i> = 109). Outcomes were assessed using standardized definitions at a median follow-up of 22 months. Treatment failure was defined according to EAU guidelines, and Kaplan-Meier analysis was applied to time-to-event outcomes. <b>Results:</b> Focal therapy patients were older, more comorbid, and had lower baseline erectile function (each <i>p</i> < 0.001). RARP was associated with the longest operative time but yielded the lowest complication rate (2.75% vs. 20.4% for HIFU and 31.5% for PGC; <i>p</i> < 0.001). Catheter-related morbidity was disproportionately higher in the PGC group. RARP conferred a longer time to treatment failure (<i>p</i> < 0.001), although continence and potency recovery at follow-up were comparable across groups. Notably, erectile function returned earlier among HIFU patients. <b>Conclusions:</b> While focal therapies offer promising early functional results with minimal perioperative risk, they are associated with earlier treatment failure and higher catheter-related morbidity, particularly after cryoablation. These findings underscore the need for individualized treatment strategies guided by standardized, comparative outcome frameworks.
Authors
- Mariaconsiglia Ferriero (ORCID: https://orcid.org/0000-0001-5188-8001)
- Gabriele Tuderti (ORCID: https://orcid.org/0000-0003-4480-9090)
- Costantino Leonardo
- Franco Lugnani (ORCID: https://orcid.org/0000-0002-7133-7052)
- Aldo Brassetti (ORCID: https://orcid.org/0000-0001-9643-8979)
- Rocco Simone Flammia (ORCID: https://orcid.org/0000-0002-3129-0544)
- Andrea Iannuzzi (ORCID: https://orcid.org/0000-0003-2619-7465)
- Riccardo Mastroianni (ORCID: https://orcid.org/0000-0003-3708-2209)
- Umberto Anceschi (ORCID: https://orcid.org/0000-0002-7586-4132)
- Alfredo Maria Bove (ORCID: https://orcid.org/0000-0002-5139-9993)
- Giuseppe Simone (ORCID: https://orcid.org/0000-0002-4868-9025)
- Flavia Proietti (ORCID: https://orcid.org/0000-0002-6478-8584)
- Salvatore Guaglianone
- Aldo Di Blasi (ORCID: https://orcid.org/0000-0003-4538-619X)
- Leonardo Misuraca (ORCID: https://orcid.org/0000-0002-6521-6289)
- Francesco Prata (ORCID: https://orcid.org/0000-0003-3084-6210)
- Rocco Papalia (ORCID: https://orcid.org/0000-0001-9566-7243)
- Eugenio Bologna
- Leslie Claire Licari
Institutions
- Università Campus Bio-Medico (IT)
- Ospedale di Rivoli (IT)
- National Cancer Institute (MY)
- Campus Bio Medico University Hospital (IT)
Publication Details
- Journal
- Cancers
- Published
- 2025-08-25
- DOI
- https://doi.org/10.3390/cancers17172762
- Citations
- 1
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52